Published in Cancer Weekly, April 17th, 2001
Dissection of this "progression-switch," marked by specific molecular events during tumor angiogenesis, could be beneficial for targeted anti-angiogenesis therapies in prostate cancer patients, the researchers say.
Medical researchers at Johns Hopkins, Emory, and Baylor Schools of Medicine performed an analysis of expression patterns during angiogenesis in an animal model dubbed TRAMP, for transgenic adenocarcinoma of the mouse prostate. Their examinations included tests for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.